Neostigmine and its salts (e.g. neostigmine bromide (INN))
Neostigmine and its salts (e.g. neostigmine bromide (INN)) 在附件 II 中被列为在欧盟市场上市的化妆品的禁用物质。
记录详情
化学名称
Neostigmine and its salts (e.g. neostigmine bromide (INN))
监管信息
关键数据
化学身份与性质

Neostigmine Bromide
Neostigmine bromide is the bromide salt of neostigmine. It contains a neostigmine. — ChEBI
- IUPAC 名称
- [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium bromide
- 分子式
- C12H19BrN2O2
- 分子量
- 303.20 g/mol
- 精确质量
- 302.06299 Da
- 拓扑极性表面积
- 29.5 Ų
- 氢键供体
- 0
- 氢键受体
- 3
- 共价单元
- 2
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:179557
- ChEMBL:CHEMBL54126
- EPA DTXSID:DTXSID9041075
- PubMed:1853
来自其他科学数据库的证据
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Solubility: >45.5 [ug/mL] (The mean of the results at pH 7.4) 来源: Sanford-Burnham Center for Chemical Genomics
- Signal: Danger 来源: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H300 (95.1%): Fatal if swallowed [Danger Acute toxicity, oral]; H310 (95.1%): Fatal in contact with skin [Danger Acute toxicity, dermal]; H315 (97.6%): Causes skin irritation [Warning Skin corrosion/irritation]; H317 (95.1%): May cause an allergic skin reaction [Warning Sensitization, Skin]; H319 (97.6%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H330 (95.1%): Fatal if inhaled [Danger Acute toxicity, inhalation]; H334 (95.1%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]; H335 (95.1%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation] 来源: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P233, P260, P261, P262, P264, P264+P265, P270, P271, P272, P280, P284, P301+P316, P302+P352, P304+P340, P305+P351+P338, P316, P319, P320, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P361+P364, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 来源: European Chemicals Agency (ECHA)
映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录
科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。
其他来源的覆盖范围和匹配状态
| 来源 | 结果 | 已检查 |
|---|---|---|
| NIH PubChem PUG-View | 精确匹配 | 2026-08-31 |
已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。
于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。
Neostigmine and its salts (e.g. neostigmine bromide (INN)) 的相关记录
该记录的直接匹配结果有限,因此同时显示附件 II 中的相邻条目。
1- and 2-Naphthylamines and their salts
附件 II 对 Neostigmine and its salts (e.g. neostigmine bromide (INN)) 意味着什么
Neostigmine and its salts (e.g. neostigmine bromide (INN)) 被列为欧盟化妆品法规 1223/2009 附件 II 中的禁用物质,不得有意添加。第 17 条另行规定了在良好生产规范下技术上不可避免、且符合第 3 条安全要求的非有意微量存在的情形。
配方师必须筛查其成分和原料,确保均不含该物质。供应商应在被要求时提供证明不含该物质的文件。
本页还显示 12 条相关附件记录,其标识符、附件逻辑或命名模式存在重叠。
合规核查清单
- 核实该物质不存在于所有原料和成品配方中。
- 向原料供应商索取不含该物质的确认函或 CoA。
- 将筛查结果记录在产品信息档案 (PIF) 中。
常见问题
附件 II 记录 Neostigmine and its salts (e.g. neostigmine bromide (INN)) 的来源说明
本页概述欧盟委员会公开化妆品资料中 Neostigmine and its salts (e.g. neostigmine bromide (INN)) 的一条附件 II 记录,并在可用时补充关联的清单或标识符匹配。
请使用本记录页面查看 Neostigmine and its salts (e.g. neostigmine bromide (INN)) 的附件 II 条件,但任何最终监管决定都应对照现行官方附件措辞和来源文件确认。